Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. Journal of Clinical Investigation. 2024. 134. 7
Daisuke Hazama, Kenji Nakahama, Hiroaki Kodama, Akito Miyazaki, Koichi Azuma, Yosuke Kawashima, Yuki Sato, Kentaro Ito, Yoshimasa Shiraishi, Keita Miura, et al. Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma. JTO clinical and research reports. 2024. 5. 1. 100613-100613
Yasushi Goto, Hirotsugu Kenmotsu, Motohiro Tamiya, Shuji Murakami, Takayasu Kurata, Noriko Yanagitani, Hirokazu Taniguchi, Shoichi Kuyama, Junichi Shimizu, Toshihide Yokoyama, et al. A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan. JTO Clinical and Research Reports. 2023. 4. 5. 100508-100508
Yasuo Otsuka, Yoriaki Komeda, Masayuki Takeda, Takayuki Takahama, Masashi Kono, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo. Long-Term Survival of More than 5 Years with Maintenance Therapy Using Single-Agent Pemetrexed in a Patient with Diffuse Malignant Peritoneal Mesothelioma. Case Reports in Medicine. 2023. 2023. 1-4